Onglyza Pancreatic Cancer Risk: Persons Taking the Diabetes Drug Onglyza
Should Be Aware of the Increased Health Risk of Pancreatic Cancer That
They May Face From Onglyza by Onglyza Pancreatic Cancer Lawyer Jason S.
Coomer
Recent scientific studies have shown that several diabetes drugs including Onglyza may cause an increased risk of pancreatic cancer. Persons taking Onglyza or saxagliptin should be aware of the potential danger of pancreatic cancer that they face and discuss the risks of this drug with their health care provider. If you have been taking the diabetes drug Onglyza and have been diagnosed with Pancreatic Cancer or you have lost a loved one from pancreatic cancer that was taking Onglyza, please report the adverse action to the prescribing medical doctor and FDA as soon as possible.
For persons that have been diagnosed with pancreatic
cancer or families that have a loved one that has been diagnosed with
pancreatic cancer, please feel free to send an e-mail message to Onglyza Pancreatic Cancer Lawyer Jason Coomer.
Onglyza (Saxagliptin) Is An Oral Diabetes Medication
Onglyza (saxagliptin) is a relatively new oral diabetes drug that is manufactured by Bristol-Myers Squibb and has been aggressively marketed and sold throughout the World. This agressive marketing and sales has been extremely successful and Onglyza (saxagliptin) sales are one of the fastest growing diabetes drug sales in the World.
Onglyza (saxagliptin) is an oral diabetes
medicine that helps control blood sugar levels. It works by regulating
the levels of insulin your body produces after eating. Onglyza (saxagliptin) is for people with type 2 diabetes. Onglyza (saxagliptin) is sometimes used in combination with other diabetes medications.
For more information about Onglyza (saxagliptin) Pancreatic Cancer Lawsuits and reporting adverse events of Onglyza, please go to the following web page: Onglyza Pancreatic Cancer Lawsuit Information and Saxagliptin Pancreatic Cancer Lawsuit Information.
No comments:
Post a Comment